search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Endoscopic Balloon Dilatation of narrowed intestinal connection in Crohn's disease with or without extra local medication


- candidate number3622
- NTR NumberNTR1378
- ISRCTNISRCTN wordt niet meer aangevraagd
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR14-jul-2008
- Secondary IDs 
- Public TitleEndoscopic Balloon Dilatation of narrowed intestinal connection in Crohn's disease with or without extra local medication
- Scientific TitleEndoscopic Balloon Dilatation of stenotic ileocecal anastomosis in Crohn's disease with or without additive local steroid injection and oral Budenofalk; a double blind, randomized, parallel group trial
- ACRONYMENDO-ACE
- hypothesisIt is beneficial to add intensive local anti-inflammatory therapy (Triamcinolone injection therapy combined with 9 mg oral BudenoFalk once daily for 24 weeks) to routine enteric balloon dilatation in Crohn's disease patients with symptomatic anastomosis.
- Healt Condition(s) or Problem(s) studiedCrohn's disease, Triamcinolone injections, Anastomosis, Ileocecal resection, Stenosis , Endoscopic balloon dilatation
- Inclusion criteria1. Informed consent
2. Man or woman between 18 and 75 years of age
3. Established diagnosis of Crohn's disease
4. Negative stool culture (for exclusion of infectious ileocolitis and Clostridium Difficile infection)
5. History of ileocecal resection
6. Symptoms of intestinal obstruction;
- Intermittent abdominal pain
- Abdominal distension
- Nausea
- Vomiting
- Anorexia
- Significant stenotic segment (defined as a decrease in calibre of the intestinal lumen causing a pre-stenotic dilatation) located at the anastomosis as diagnosed with MR enterography.
- Exclusion criteria1. A stenotic segment of more than 6 cm
2. Rutgeerts score i4 inflammation at the site of stenosis
3. Fistulas at the site of stenosis or in the near proximity
4. A stenosis that cannot be properly endoscopically visualized
5. A significant stenosis proximal to the stenotic anastomosis 6. The concomitant use of other oral drugs containing budesonide within 4 weeks of screening
7. Oral antibiotics within 4 weeks of screening.
8. Pregnancy, lactation, or intended pregnancy or intended impregnation within 9 months
9. Serious secondary illnesses of an acute or chronic nature (e.g., acute cardiovascular disease, active infection)
10. Active infection
11. Known intolerance/hypersensitivity to the study drug
12. Well-founded doubt about the patient's cooperation and/or compliance
- mec approval receivedno
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-okt-2008
- planned closingdate1-okt-2008
- Target number of participants36
- Interventions- Triamcinolone injection therapy combined with 9 mg oral BudenoFalk once daily for 24 weeks
- IBDQ, Harvey-Bradshaw score and VAS scores will be obtained at defined points.
- MR enterography will be performed.
- Colonoscopy with fluoroscopy under conscious sedation.
- Asessment of Rutgeerts score during colonoscopy.
- An EBD will be performed during the same colonoscopy session.
- At defined points blood samples will be taken
- Primary outcomeTo evaluate the benefit of the addition of intensive local anti-inflammatory therapy to routine enteric balloon dilatation in Crohn´s disease patients with symptomatic stenosis of the anastomosis.
- Secondary outcome- To assess the feasibility of radiologic imaging of the anastomosis in the endoscopy suite, and validating Radiological Crohn´s Disease Anastomotic Index (RCDAI).
- To assess the safety of EBD procedure in combination with local intensive therapy
- Timepoints- Triamcinolone injection therapy combined with 9 mg oral BudenoFalk once daily for 24 weeks
- 1/10/2008 - 1/10/2010
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIESDrs. C.G. Noomen
- CONTACT for SCIENTIFIC QUERIESDrs. C.G. Noomen
- Sponsor/Initiator Leiden University Medical Center (LUMC), Department of Gastroenterology and Hepatology
- Funding
(Source(s) of Monetary or Material Support)
Leiden University Medical Center (LUMC), Department of Gastroenterology and Hepatology
- PublicationsN/A
- Brief summaryThe primary objective of this study is to evaluate the benefit of adding intensive local anti-inflammatory therapy (Triamcinolone injection therapy combined with 9 mg oral BudenoFalk once daily for 24 weeks) to routine enteric balloon dilatation in Crohn´s disease patients with symptomatic anastomosis
- Main changes (audit trail)
- RECORD14-jul-2008 - 25-jul-2008


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl